Theratechnologies (TSE:TH) Hits New 1-Year High - Time to Buy?

Key Points

• Theratechnologies shares reached a new 52-week high of C$4.44 during mid-day trading, with a recent trading price of C$4.43 and a market cap of C$141.02 million.
• Wall Street analysts from Jones Trading have downgraded the company from a "strong-buy" to a "hold" rating, indicating a cautious outlook on the stock's performance.
• The company specializes in addressing the unmet medical needs of HIV patients, operating mainly in Canada and the United States, with two approved products in its portfolio.

Theratechnologies Inc. (TSE:TH - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as C$4.44 and last traded at C$4.43, with a volume of 1828 shares. The stock had previously closed at C$4.41.

Analyst Ratings Changes

Separately, Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.

Theratechnologies Stock Up 0.2%

The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of -293.92. The stock has a market cap of C$142.94 million, a PE ratio of -50.71, a P/E/G ratio of -8.50 and a beta of 1.73. The business has a 50 day moving average price of C$3.99 and a 200 day moving average price of C$3.27.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.